STAT3 and non-small cell lung carcinoma: In NSCLC, PROTACs have shown promise against transcription factors such as STAT3 analogs, but face hurdles in E3 ligase selectivity (risking off-target toxicity) and dependency on endogenous ubiquitin machinery (126,127).